In the first part of the series introducing health, wellness and life science investors we introduced Finland-based investors. This second part of the series consists of introductions of investors based and investing in Scandinavia. The information here is gathered from the websites and introduces only the very basics of each investor, so use the links and go find out more!
BirkVenture is a Scandinavian venture company that offers venture capital to companies and entrepreneurs in life sciences. Their office is in Oslo. In their investments, they focus in pharmaceuticals, biotechnology, diagnostics, medical devices and instruments, and consumer
health, and they look for attractive, long-term business cases and companies in their early stages.
HealthCap is a family of multi stage venture capital funds, investing globally in life sciences, with offices in Stockholm and Lausanne, Switzerland. They invest in the commercialization of innovations in medical science, focusing in pharmaceutical, biotechnology and medical technology companies. The investments are made in early-stage opportunities as well as in
more mature companies.
Incitia Ventures is an independent Nordic VC fund manager based in Oslo. They invest in technology companies in the start-up and expansion phase within broad range of technology sectors. Incitia Ventures has hands-on involvement in companies so they invest in and nurture only a few investments at a time.
Innovationskapital is an independent early stage venture capital firm for innovative growth companies in the Nordic region. They focus in early-stage companies in the areas of ICT, healthcare and life sciences.
Innoventus’ mission is to develop novel technology concepts and transform those into objects of visible and measurable commercial value. They invest in biotech and life science companies in the phase where technology ventures are too immature to meet traditional investment criteria. The geographic area of their investments is not defined, the headquarters are in Uppsala, Sweden.
Lundbeckfond Ventures is a venture fund investing in life science companies. It is owned by Lundbeck Foundation. The focus of their investments is in clinical pharmaceuticals and biopharmaceuticals, medtech, diagnostics, and healthcare service companies in northern Europe.
Novo Seeds is a life science supporting program that consists of a pre-seed fund and a seed fund. Their aim is to identify and develop into successful businesses the unexplored commercial potential in the academic and early stage applied research projects at universities and biotech companies in Scandinavia. See also other Novo Group investors, Novo Ventures and Novo Growth Equity.
NXT2B is a privately owned venture capital company with offices in Uppsala, Sweden. They invest with long term commitment in healthcare, medical device, and specialty pharmaceutical companies in their early phases. The focus is in projects with high scientific quality with reasonable business opportunities.
SLS Invest is a Scandinavian investor focusing in life science companies in Scandinavia. They invest in small and mid-sized companies in late product development, launch or product line extension phases.
Sunstone Life Science Ventures is a European investor based in Copenhagen. They invest in early-stage life science companies with focus in therapeutics, medtech, and diagnostics. The point of entry of the investment depends on the type of life science opportunity. Their geographic focus is especially in Nordic countries, Germany and Switzerland.
Vanadis Capital combines life science business knowledge, hands-on operational expertise and medical background in providing human and financial resources in acceleration of product validation, end-user alignment, market access and early growth. They focus on biotechnologies,
diagnostics, medical devices and services, and pharmaceuticals in northern Europe.
Hopefully these northern investor links are useful to you. Let us know if we missed someone who should be on the list. In the next blogpost we turn the attention to investors acting in wider
European scale, and finally in the fourth post we will wrap up the different healthtech business accelerators.